Address: Orionintie 1, P.O. Box 65, FI-02101 Espoo, Finland
Tel: +35810 4261
Fax:

Orion Corporation

Orion Corporation operates globally as a highly innovative R&D based manufacturer and provider of ethical quality pharmaceuticals and diagnostics. As a CMO, Orion also offers added value pharmaceutical contract manufacturing services for global markets. Since 1917, the company’s mission has been to build well being through innovation; initially in its native country Finland and now with direct presence in 21 European countries. Through its own sales offices, and a comprehensive partner network, Orion provides its products to more than 100 countries worldwide.

Orion continuously develops new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs as well as asthma and chronic obstructive pulmonary disease (COPD).

Orion and Fermion product and service offerings involve APIs and finished dosage forms as well as a capable marketing and sales network made available for partners’ licensing opportunities.

Quality & certification

Orion supplies to all global markets from facilities that comply with requirements from authorities in North America, Europe, Japan, Latin America and Middle East. Orion’s facilities are regularly inspected by EMA, FDA, JP and ANVISA.

Activities

Orion has five principal business streams:

Contract manufacturing

Orion offers high value pharmaceutical CMO services for world markets with a contract manufacturing portfolio that includes proprietary and generic products for human and animal health in various dosage forms.

As a full-scale pharma company, Orion has broad experience in providing clients with extensive contract manufacturing services that range from R&D support to regulatory know-how and comprehensive supply chain operations.

The CMO business is based on acknowledged quality of operations, profound expertise in technology transfers, solid project management practices, excellent customer service and high service levels, all backed by a well established organization and strong financial position.

Orion has four pharmaceutical plants, all located in Finland. These offer the following dosage forms for pharmaceutical contract manufacturing and packaging:

  • Hormonal gels and solutions
  • Small volume parenterals (injectable solutions in vials and ampoules)
  • Solid oral dosage forms (tablets, capsules
  • Liquids (solutions, suspensions, drops, nasal drops and nasal sprays)
  • Semi solids (creams, gels and ointments)
  • Cytostatics (tablets, capsules)

Hormonal products are a specialty area for Orion, which has more than 20 years of experience in developing and manufacturing these as semi-solid gels and solutions.

Orion also has deep experience with potent APIs and controlled substances, in handling flammable liquids, in finding solutions for formulation and analytical challenges and in various packaging formats.

Active pharmaceutical ingredients

The fully-owned subsidiary Fermion markets a wide range of generic APIs under its own brand.

Fermion also manufactures APIs for Orion’s proprietary products as well as offering CMO manufacturing services for APIs, including highly potent compounds. Fermion has particular expertise in manufacturing anticancer products.

Read more about Fermion at http://www.fermion.fi

Prescription drugs and self-care

Orion markets a wide range of primary healthcare prescription drugs and other products for treatment and prevention of commonest illnesses. The portfolio consists of almost 400 products including proprietary drugs developed by Orion, substitutable generics and patented drugs in licensed from other pharmaceutical companies and self-care products such as non-prescription medicines, basic ointments and vitamins.

Proprietary drugs include the intensive care sedatives Precedex ®and dexdor® (API dexmedetomidine), the Parkinson’s disease medication Stalevo® (levodopa, carbidopa, entacapone), Simdax® (levosimendan) for acute decompensated heart failure, and Fareston® (toremifene) for breast cancer.

Orion has also developed the Easyhaler® range of metered-dose dry powder inhalers and products for treatment of asthma and COPD.

Veterinary drugs

Orion’s veterinary drugs are widely recognized in the Nordic countries. The company’s own manufactured proprietary veterinary products include:

  • Domitor® (medetomidine) and Dexdomitor® (dexmedetomidine) sedatives for small animals such as cats and dogs
  • Domosedan® (detomidine) sedative and analgesic for horses and other large animals
  • Antisedan® (atipamezole) antagonist for reviving a sedated animal
  • Kefavet® (cephalexin) antibiotic for cats and dogs
  • Comforion® (ketoprofen) NSAIDs particularly for cattle
  • Broilact® anti-enteropathogen protection for poultry

Orion also manufactures animal health generics and markets and sells veterinary drugs manufactured by several international companies. It also manufactures and markets the popular range of Aptus® nutritional food supplements for dogs and cats.

Diagnostic tests

Orion Diagnostica promotes well-being by offering accurate and affordable clinical diagnostic and hygiene monitoring tests that are easy to use and provide fast results.

The company develops, manufactures and markets in vitro diagnostic test systems and tests for diagnosing diseases and monitoring treatment efficacy. The focus is on point-of-care solutions, which can be used near the patient. Orion hygiene tests can be used, for example, to monitor surface cleanliness.

Orion Diagnostica promotes products to global healthcare and hygiene customers in more than 60 countries and also engages in contract manufacturing of diagnostic products for other companies.

Structure and locations

Orion is a clear sales leader in its main market in Finland and also offers its products in more than 100 countries worldwide. Orion´s human pharmaceuticals sales organisation covers almost all key European markets. Several collaboration partners distribute Orion products in overseas markets.

The wholly owned Fermion subsidiary concentrates on researching and manufacturing APIs.

All Orion manufacturing and most of its R&D operations are in Finland, with the group headquarters in Espoo, a short distance west of Helsinki. Orion employs some 3,500 people worldwide. In 2013, reported global sales passed the one billion Euros mark. Orion A and B shares are listed on NASDAQ OMX Helsinki.

Contact

To learn more about Orion's services and capabilities and how they can assist your business, please contact Orion directly.



Follow us on:
Groups:
  • CRO, CMO, CRAMS & CDMO
  • Formulation & Ingredients
  • Manufacturing & Production
  • Packaging & Labelling